This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription drugs for millions of people with Medicare. The law laid out aggressive timelines for implementing the Medicare DrugPrice Negotiation Program.
billion in revenue by dispensing medicines to treat cancer, HIV, heart disease and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. The FTC noted in its report that so-called specialty generic drugs represent a large and growing amount of spending by plan sponsors and patients.
WASHINGTON — The deadline for announcing how much Medicare lowered drugprices in the first year of negotiation is Sept. In 2022, Democrats directed Medicare to negotiate drugprices for the first time as part of the Inflation Reduction Act. The first 10 drugs selected for negotiation accounted for $3.4
WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drugprice negotiation program managed to find themselves a Democratic co-sponsor — even though every single Democrat in Congress in 2022 voted for the legislation.
At the same time, net prices health plans paid for medicines — after subtracting rebates, discounts, and fees — dropped by 0.4%. But again, after considering inflation, net prices actually fell 8.5%, compared with 8.2% in the third quarter of 2022. Continue to STAT+ to read the full story…
30, five gave to Democratic candidates, even though Democratic lawmakers passed the most aggressive drugpricing reform in decades in 2022. But of the six executives who donated to individual candidates between July 1 and Sept. Continue to STAT+ to read the full story…
WASHINGTON — Three large pharmaceutical companies left the brand-drug lobby PhRMA after the passage of Democrats’ drugpricing law in 2022. Following the exits, the organization collected $100 million less in annual membership dues, new tax filings show. Continue to STAT+ to read the full story…
It is also the latest instance in a growing trend of pharmaceutical companies re-evaluating their memberships in large trade groups following a historic lobbying loss when Democrats passed a new drug-pricing reform law in August 2022.
The Inflation Reduction Act, passed by Democrats in 2022, made several changes to Medicare’s drug benefit, known as Medicare Part D. All were aimed at lowering drugprices and drug costs for both seniors and the federal government.
The Inflation Reduction Act of 2022 mandates that Medicare-covered drug sales will be protected from price increases that exceed inflation, but the mechanics of this “inflation penalty” have generated some confusion.
During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $1.2 billion last year, according to a new report.
And after 20 years, they finally delivered on a promise to empower the federal government to lower drugprices in 2022. They have campaigned on passing health insurance reform, and then protecting it. But the remaining elephant in the room is hospital costs, which make up the biggest share of U.S. health care spending.
DrugPricing Transparency Congress. Hybrid Event March 28-29, 2022 | Philadelphia, PA www.informaconnect.com/drug-pricing-transparency. Don’t miss the DrugPricing Transparency Congress on March 28-29, 2022! Drug Channels, or any of its employees. Drug Channels, or any of its employees.
In this video, we chat with health policy and drugpricing researcher Hussain Lalani; Julia Joung, a molecular biologist developing genetic screening technologies; and Avinash Manjula Basavanna, who researches engineered living materials and has developed a printable ink made from bacteria.
Challenging market conditions, driven by drugpricing pressures, regulatory shifts, and geopolitical tensions, have reshaped the landscape, offering both hurdles and opportunities for contract manufacturing organisations (CMOs) to adapt and innovate amidst global generic shortages, reveals GlobalData.
In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed Amgen drug used to treat arthritis, a step that may usher in a new era in which state governments take more aggressive action to control the cost of prescription medicines.
The Inflation Reduction Act of 2022 , which includes provisions requiring Medicare to negotiate lower drugprices for some of the United States’ most costly drugs, marks the first time in decades that the pharmaceutical industry has lost a major policy battle. The industry’s latest red herring ?
It's time for Drug Channels annual examination of U.S. brand-name drugpricing. For 2024, average brand-name drugs list prices grew by only 2.3%. Whats more, after adjusting for overall inflation, brand-name drug net prices dropped for an unprecedented seventh consecutive year.
But by most financial measures, 2022 was a terrible, horrible, no-good year for biotech — here and everywhere else. And a new federal law to combat high drugprices sent a chill down the industry’s spine. And a new federal law to combat high drugprices sent a chill down the industry’s spine.
Pharma’s dwindling alliances The pharmaceutical industry didn’t have many friends that stuck up for it when Democrats passed a historic drugpricing law in 2022. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Time for the Drug Channels annual reality check on drugpricing. For 2022, brand-name drugs’ net prices dropped for an unprecedented fifth consecutive year. What’s more, after adjusting for overall inflation, brand-name drug net prices plunged by almost 9%. d/b/a Drug Channels Institute.
Time for the Drug Channels annual reality check on drugpricing. For 2022, brand-name drugs’ net prices dropped for an unprecedented fifth consecutive year. What’s more, after adjusting for overall inflation, brand-name drug net prices plunged by almost 9%. d/b/a Drug Channels Institute.
When rebates and discounts were factored in, brand-name drugprices again declined—or grew slowly—in 2022. However, some companies had net price gains. For the eight companies with multiple years of data, the gross-to-net difference in price changes was the smallest gap in six years. d/b/a Drug Channels Institute.
When rebates and discounts were factored in, brand-name drugprices again declined—or grew slowly—in 2022. However, some companies had net price gains. For the eight companies with multiple years of data, the gross-to-net difference in price changes was the smallest gap in six years. See the second chart below.
Drug Channels has just obtained new details on the size of the 340B DrugPricing Program. For 2022, discounted purchases under the 340B program reached a record $53.7 The difference between list prices and discounted 340B purchases also grew, to $52.3 Hospitals accounted for 87% of 340B purchases for 2022.
Drug Channels has just obtained new details on the size of the 340B DrugPricing Program. For 2022, discounted purchases under the 340B program reached a record $53.7 Hospitals accounted for 87% of 340B purchases for 2022. My topic #9 for 2024: The Battle Over 340B Gets Even Messier. billion —an astonishing $9.8
In Consolidation and Preferred Pharmacy Networks in 2022’s Medicare Part D Plans , I highlighted how those networks have hijacked the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans. d/b/a Drug Channels Institute.
The 340B DrugPricing Program has grown yet again , exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. drug market.
See The GoodRx-Kroger Blowup: Spread Pricing, Pharmacy Margins, and the Future of Discount Cards. In the video below, I discuss how generic drugpricing and the rise of patient-paid, discount card prescriptions pose a risk to pharmacy benefit plans and the PBM business. d/b/a Drug Channels Institute.
government’s initial approach to negotiating drugprices could discourage cheaper biosimilar versions of more complex pharmaceuticals that eat up a high portion of total Medicare spending , Bloomberg Law explains. Medicare picked its top 10 list based on total spending between June 1, 2022, and May 31, 2023.
I am pleased to announce our new 2022 Economic Report on U.S. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S. The 2022 Economic Report on U.S. Click to Enlarge].
drugpricing, reimbursement, and dispensing system. prescription dispensing revenues for calendar year 2022. prescription dispensing revenues reached a record $548 billion in 2022. It’s the 14th edition of our popular and comprehensive examination of the entire U.S.
drug distribution system Explain the effects of competition on drugpricing under provider-administered and patient-administered drugs. The paper was published in GaBI Journal, Volume 11, Year 2022, Issue 3. Read the full paper online here. Read more about the approval here. Read it Here.
2022 is probably the biggest year in EU pharmaceutical law that I have seen in 30 years. 2022 is undeniably a critical year for change in the pharmaceutical industry: for the first time in several decades, the European Union (EU)’s pharmaceutical legislation is up for review. Key areas of potential legislative change. Future outlook.
The results generated considerable excitement since a daily pill is nearly 100% effective but compliance is spotty and there is a stigma attached to regularly taking a drug for HIV. But its impact on addressing an epidemic that, as of 2022, still led to more than 1 million new infections each year is uncertain.
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The Outlook 2022 marks our third annual outlook webinar. to 1:30 p.m.
In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed Amgen drug used to treat arthritis, a step that may usher in a new era in which state governments take more aggressive action to control the cost of prescription medicines.
The vote means the board will decide in a follow-up meeting whether to pursue an upper payment limit for the drug, which an affordability review found cost an average of roughly $47,000 per patient in 2022.
Earlier this week, the Swiss agency conducted a dawn raid on Novartis headquarters in Basel, Switzerland, seeking information about efforts the company allegedly made to protect a drug for an unspecified skin treatment. billion in sales in the first half of 2022. Continue to STAT+ to read the full story…
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Click here to see the original post from May 2022. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers.
… Investors in biopharma companies, who lobbied vigorously — but unsuccessfully — against allowing Medicare to negotiate drugprices, are trying a new tactic to preserve their profits , The Boston Globe tells us. Have a grand day, and drop us a line if you hear something juicy.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content